- Previous Close
92.11 - Open
91.90 - Bid 88.30 x 200
- Ask 92.99 x 100
- Day's Range
88.21 - 91.98 - 52 Week Range
62.07 - 98.90 - Volume
11,453,515 - Avg. Volume
6,561,975 - Market Cap (intraday)
110.17B - Beta (5Y Monthly) 0.19
- PE Ratio (TTM)
982.22 - EPS (TTM)
0.09 - Earnings Date Feb 4, 2025 - Feb 10, 2025
- Forward Dividend & Yield 3.08 (3.48%)
- Ex-Dividend Date Dec 13, 2024
- 1y Target Est
95.73
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
www.gilead.com18,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GILD
View More
Performance Overview: GILD
Trailing total returns as of 11/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GILD
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GILD
View MoreValuation Measures
Market Cap
110.17B
Enterprise Value
128.38B
Trailing P/E
982.22
Forward P/E
12.03
PEG Ratio (5yr expected)
0.52
Price/Sales (ttm)
3.90
Price/Book (mrq)
5.96
Enterprise Value/Revenue
4.54
Enterprise Value/EBITDA
32.77
Financial Highlights
Profitability and Income Statement
Profit Margin
0.44%
Return on Assets (ttm)
11.96%
Return on Equity (ttm)
0.56%
Revenue (ttm)
28.3B
Net Income Avi to Common (ttm)
126M
Diluted EPS (ttm)
0.09
Balance Sheet and Cash Flow
Total Cash (mrq)
6.7B
Total Debt/Equity (mrq)
126.42%
Levered Free Cash Flow (ttm)
9.08B
Research Analysis: GILD
View MoreCompany Insights: GILD
GILD does not have Company Insights
Research Reports: GILD
View MoreBiopharma Election Impact: Potential Reduced IRA Headwind but Unpredictable Challenges
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
RatingPrice TargetGilead Earnings: Maintaining Our $97 Fair Value Estimate Following Third-Quarter Outperformance
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
RatingPrice TargetGilead Earnings: Maintaining Our $97 Fair Value as Long-Term HIV Sales Potential Looks Undervalued
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
RatingPrice TargetThe Argus High-Yield Model Portfolio
Value stocks -- a market segment that includes high-yield stocks -- outperformed growth stocks in 2022. That's a recent rarity, as for the past decade-plus, the performance record has favored growth. But in 2022, The rollout of COVID-19 vaccines gave a lift to some of the cyclical companies (energy and regional banks) that had lagged in recent quarters, and value stocks outpaced growth stocks that year. While growth stocks have retaken the lead since 2023, the Federal Reserve continues to keep interest rates high to fend off inflation. This could possibly cap multiple expansion for growth companies in coming quarters. In any event, the value sector is the place to achieve income.